We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Axsome Therapeutics Inc | NASDAQ:AXSM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.07 | 1.41% | 77.00 | 76.00 | 77.35 | 77.48 | 74.71 | 76.01 | 422,941 | 00:26:22 |
From May 2021 to May 2024
By Colin Kellaher
Axsome Therapeutics Inc. on Tuesday said it plans to file for U.S. Food and Drug Administration approval of AXS-14 for the management of fibromyalgia by the end of next year.
The New York biopharmaceutical company said a pair of placebo-controlled trials have shown the potential for AXS-14 to improve the symptoms of the debilitating central-nervous-system condition, which currently has limited treatment options.
Axsome said it plans to submit a new drug application for AXS-14 in the fourth quarter of 2022, pending successful completion of manufacturing and other activities related to the product candidate.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 15, 2021 08:16 ET (12:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Axsome Therapeutics Chart |
1 Month Axsome Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
